420 related articles for article (PubMed ID: 26759363)
21. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.
Freeman J; Baines SD; Saxton K; Wilcox MH
J Antimicrob Chemother; 2007 Jul; 60(1):83-91. PubMed ID: 17483547
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.
Chilton CH; Crowther GS; Baines SD; Todhunter SL; Freeman J; Locher HH; Athanasiou A; Wilcox MH
J Antimicrob Chemother; 2014 Mar; 69(3):697-705. PubMed ID: 24128668
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.
Ochsner UA; Bell SJ; O'Leary AL; Hoang T; Stone KC; Young CL; Critchley IA; Janjic N
J Antimicrob Chemother; 2009 May; 63(5):964-71. PubMed ID: 19251726
[TBL] [Abstract][Full Text] [Related]
24. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection.
Rätsep M; Kõljalg S; Sepp E; Smidt I; Truusalu K; Songisepp E; Stsepetova J; Naaber P; Mikelsaar RH; Mikelsaar M
Anaerobe; 2017 Oct; 47():94-103. PubMed ID: 28465256
[TBL] [Abstract][Full Text] [Related]
25. Lactoferrin-Loaded Alginate Microparticles to Target Clostridioides difficile Infection.
Braim S; Śpiewak K; Brindell M; Heeg D; Alexander C; Monaghan T
J Pharm Sci; 2019 Jul; 108(7):2438-2446. PubMed ID: 30851342
[TBL] [Abstract][Full Text] [Related]
26. A new strategy for the prevention of Clostridium difficile infection.
Howerton A; Patra M; Abel-Santos E
J Infect Dis; 2013 May; 207(10):1498-504. PubMed ID: 23420906
[TBL] [Abstract][Full Text] [Related]
27. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut.
Freeman J; O'Neill FJ; Wilcox MH
J Antimicrob Chemother; 2003 Jul; 52(1):96-102. PubMed ID: 12775682
[TBL] [Abstract][Full Text] [Related]
28. Control of an outbreak of diarrhoea in a vascular surgery unit caused by a high-level clindamycin-resistant Clostridium difficile PCR ribotype 106.
Ratnayake L; McEwen J; Henderson N; Nathwani D; Phillips G; Brown D; Coia J
J Hosp Infect; 2011 Nov; 79(3):242-7. PubMed ID: 21864938
[TBL] [Abstract][Full Text] [Related]
29. Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production.
Chilton CH; Crowther GS; Ashwin H; Longshaw CM; Wilcox MH
PLoS One; 2016; 11(8):e0161200. PubMed ID: 27556739
[TBL] [Abstract][Full Text] [Related]
30. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.
Baines SD; Freeman J; Wilcox MH
J Antimicrob Chemother; 2005 Jun; 55(6):974-82. PubMed ID: 15860551
[TBL] [Abstract][Full Text] [Related]
31. Dynamics and establishment of Clostridium difficile infection in the murine gastrointestinal tract.
Koenigsknecht MJ; Theriot CM; Bergin IL; Schumacher CA; Schloss PD; Young VB
Infect Immun; 2015 Mar; 83(3):934-41. PubMed ID: 25534943
[TBL] [Abstract][Full Text] [Related]
32. Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism.
Gupta I; Sehgal R; Kanwar RK; Punj V; Kanwar JR
Nanomedicine (Lond); 2015; 10(8):1289-314. PubMed ID: 25442715
[TBL] [Abstract][Full Text] [Related]
33. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.
Gerding DN; Meyer T; Lee C; Cohen SH; Murthy UK; Poirier A; Van Schooneveld TC; Pardi DS; Ramos A; Barron MA; Chen H; Villano S
JAMA; 2015 May; 313(17):1719-27. PubMed ID: 25942722
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Chicken IgY Specific to
Pizarro-Guajardo M; Díaz-González F; Álvarez-Lobos M; Paredes-Sabja D
Front Cell Infect Microbiol; 2017; 7():365. PubMed ID: 28856119
[No Abstract] [Full Text] [Related]
35. Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea.
Kim J; Kang JO; Kim H; Seo MR; Choi TY; Pai H; Kuijper EJ; Sanders I; Fawley W
Clin Microbiol Infect; 2013 Jun; 19(6):521-7. PubMed ID: 22712697
[TBL] [Abstract][Full Text] [Related]
36. Antioxidant enzyme activities of iron-saturated bovine lactoferrin (Fe-bLf) in human gut epithelial cells under oxidative stress.
Burrow H; Kanwar RK; Kanwar JR
Med Chem; 2011 May; 7(3):224-30. PubMed ID: 21486205
[TBL] [Abstract][Full Text] [Related]
37. [Presence of lactoferrin in faeces as the indicator of Clostridium difficile in pediatric patients].
Dąbrowskal S; Demkow U; Podsiadły E
Med Dosw Mikrobiol; 2015; 67(1):1-8. PubMed ID: 26084069
[TBL] [Abstract][Full Text] [Related]
38. Effect of selenium-saturated bovine lactoferrin (Se-bLF) on antioxidant enzyme activities in human gut epithelial cells under oxidative stress.
Burrow H; Kanwar RK; Mahidhara G; Kanwar JR
Anticancer Agents Med Chem; 2011 Oct; 11(8):762-71. PubMed ID: 21919840
[TBL] [Abstract][Full Text] [Related]
39. Structural characteristic, pH and thermal stabilities of apo and holo forms of caprine and bovine lactoferrins.
Sreedhara A; Flengsrud R; Langsrud T; Kaul P; Prakash V; Vegarud GE
Biometals; 2010 Dec; 23(6):1159-70. PubMed ID: 20680664
[TBL] [Abstract][Full Text] [Related]
40. Experimental Clostridium difficile enterocolitis in foals.
Arroyo LG; Weese JS; Staempfli HR
J Vet Intern Med; 2004; 18(5):734-8. PubMed ID: 15515592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
